Leerink Partnrs Reaffirms “Outperform” Rating for AnaptysBio (NASDAQ:ANAB)

Leerink Partnrs reiterated their outperform rating on shares of AnaptysBio (NASDAQ:ANAB) in a report published on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for AnaptysBio’s Q1 2024 earnings at ($1.41) EPS, Q2 2024 earnings at ($1.44) EPS, Q3 2024 earnings at ($1.45) EPS, Q4 2024 earnings at ($1.42) EPS, FY2024 earnings at ($5.71) EPS, Q1 2025 earnings at ($1.91) EPS, Q2 2025 earnings at ($1.86) EPS, Q3 2025 earnings at ($1.85) EPS, Q4 2025 earnings at ($1.14) EPS, FY2025 earnings at ($6.37) EPS, FY2026 earnings at ($4.82) EPS, FY2027 earnings at ($3.95) EPS and FY2028 earnings at ($3.39) EPS.

Several other brokerages also recently commented on ANAB. BTIG Research began coverage on AnaptysBio in a research note on Monday, February 26th. They set a buy rating and a $55.00 price objective on the stock. Stifel Nicolaus started coverage on AnaptysBio in a research note on Wednesday, February 21st. They set a buy rating and a $50.00 price objective on the stock. Wedbush raised AnaptysBio from a neutral rating to an outperform rating and lifted their price target for the company from $20.00 to $34.00 in a research note on Tuesday, March 12th. Wells Fargo & Company started coverage on AnaptysBio in a research note on Thursday, April 11th. They issued an overweight rating and a $56.00 price target on the stock. Finally, JPMorgan Chase & Co. dropped their price target on AnaptysBio from $30.00 to $28.00 and set a neutral rating on the stock in a research note on Monday, April 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus target price of $46.22.

AnaptysBio Trading Down 7.6 %

Shares of AnaptysBio stock opened at $19.83 on Tuesday. The company has a market capitalization of $530.65 million, a PE ratio of -3.26 and a beta of -0.30. AnaptysBio has a 12 month low of $13.36 and a 12 month high of $27.50. The stock’s fifty day simple moving average is $23.31 and its 200 day simple moving average is $20.54.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Monday, March 11th. The biotechnology company reported ($1.59) EPS for the quarter, topping the consensus estimate of ($1.74) by $0.15. The business had revenue of $9.01 million for the quarter, compared to the consensus estimate of $3.28 million. AnaptysBio had a negative return on equity of 119.42% and a negative net margin of 953.66%. Analysts predict that AnaptysBio will post -6.25 EPS for the current fiscal year.

Insider Activity

In other news, CEO Daniel Faga sold 145,940 shares of the firm’s stock in a transaction dated Friday, March 22nd. The stock was sold at an average price of $22.78, for a total value of $3,324,513.20. Following the completion of the transaction, the chief executive officer now owns 752,087 shares in the company, valued at approximately $17,132,541.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Daniel Faga sold 145,940 shares of the firm’s stock in a transaction dated Friday, March 22nd. The stock was sold at an average price of $22.78, for a total value of $3,324,513.20. Following the completion of the transaction, the chief executive officer now owns 752,087 shares in the company, valued at approximately $17,132,541.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Dennis Mulroy sold 3,065 shares of the firm’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $23.63, for a total value of $72,425.95. Following the completion of the transaction, the chief financial officer now owns 964 shares of the company’s stock, valued at approximately $22,779.32. The disclosure for this sale can be found here. Insiders sold 157,005 shares of company stock worth $3,586,199 in the last quarter. Corporate insiders own 35.50% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

Hedge funds and other institutional investors have recently bought and sold shares of the business. Quantbot Technologies LP bought a new position in AnaptysBio during the second quarter worth about $34,000. Allspring Global Investments Holdings LLC bought a new position in AnaptysBio during the first quarter worth about $38,000. Tower Research Capital LLC TRC grew its holdings in AnaptysBio by 248.8% during the third quarter. Tower Research Capital LLC TRC now owns 3,596 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 2,565 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in AnaptysBio by 350.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 2,390 shares during the period. Finally, BNP Paribas Arbitrage SA grew its holdings in AnaptysBio by 75.4% during the second quarter. BNP Paribas Arbitrage SA now owns 4,984 shares of the biotechnology company’s stock worth $101,000 after purchasing an additional 2,142 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.